





Thanks to our generous sponsors





World Health Organization











Title of Presentation

Use of Supply Chain Data for Program Quality Monitoring:

Trends in Use of ALU in Malaria Case management- Morogoro Municipal Experience

Godbless Mariki^{1*}, Joseph Mugasa², John Gamaliel², Beatrice Christian¹ Emeka Okechukwu² Patrick Swai³, Marina Njelekela⁴

Global Healt Supply Chains. Accra, Ghana 2017



Contents

- Introduction
- Methodology
- Results
- Conclusion





Introduction

- First line antimalarial treatment has been Artemether/Lumefantrine (ALU)
- Availability of ALU depends on;
 - Logistics data reported to the central level, for

Quantification, procurement, distribution and delivery schedules

- Supply chain data provides critical information to complement other program data points and monitor quality of care provided to patients.
- Commodity consumption data is useful in triangulating and making sense of other service delivery data.
- ALU consumption should be the same as the malaria cases data captured in DHIS2



Introduction..

- Tools/Systems;
 - Electronic system; eLMIS for reporting logistics data and requesting resupply of health commodities by all facilities
 - ➢ DHIS2
- Aim: Review ALU consumption and Malaria cases discrepancies in Morogoro Municipal; Establish Intervention plan



Introduction..

- Supply chain data provides critical information to complement other program data points and monitor quality of care provided to patients.
- Commodity consumption data is useful in triangulating and making sense of other service delivery data.
- **Aim:** Review differences between ACT consumption and Malaria cases in Morogoro Municipal; Establish Intervention plan



Methodology

- Convenience sampling,
 - -30 Public HF's in Morogoro MC
- Retrospective review
 - Consumption data for dispensed ALU doses reported in eLMIS
 - Malaria cases from DHIS2 (mRDT, BS and Clinical) April 2016 to June 2017
 - Review of ILS dispensing




Methodology

• Data was analysed using eLMIS dashboards and Microsoft Excel 2013

e	Requisitions	Orders	Equipments	Reports	Administration I	LS Gateway			
Agg	regate Cons	umption F	Report						
Progra	am *						Ρε	age	
ILS 🔹			# Product code / name:		Product name	Reported Consumption	Reported Consumption per Packs		
Sched Grou			1 10010170BE		Artemether/Lumefantrine (Bluu 2 x 6) 20/120 mg (B/30)	493,234	16,442		
Year *	7		2 10010002BE	:	Artemether/Lumefantrine (Kahawia 3 x 6) 20/120 mg (B/30)	494,811	16,494		
	I * I - June •		3 10010171BE		Artemether/Lumefantrine (Kijani 4 x 6) 20/120 mg (B/30)	918,470	30,616		
More	ogoro MC - District	*	4 10010169BE		Artemether/Lumefantrine (Njano 1 x 6) 20/120 mg (B/30)	494,281	16,477		




Comparison of number of Malaria cases and ACT consumption








ACT Consumption Vs mRDT












• SS and mentorship to 30 reporting facilities in the municipality focus on compliance to the national malaria treatment guideline and data quality



Differences Expiry dates affecting dispensing trends





• Dispensing of Multiple paediatric formulations for Adults due to Shelf Life

		100													-		
	Vo.	a	ALF	FR	EQ	U	EI	TN	THE T	Y	U	S	E	D	D	R	ι
	PRESCRIPTION No.	OF SUBSCRIBER	Numi Johng	R	Prenovymetry Pencilin tabe 250mg Oproficeach tabe 500mg Erythrenych Gravues 125mg5mi Antoncilin Gravues 125mg5mi 100me Go Miniorazde Sissension 2004dang5mi 100me Benzahne Pencilin Fostekel Beit File 34 km		F Inj 4 mu		Benote Act Comparing the package Attended Landstating 20120 mg Blass 2 att Annether Landstating 20120 mg Blass 2 att	ng (Naturna an			W of Acids tables 2004-0.25 mg	nd tabs he powder	Sym 10mg CO-PACK		of 0.03 mg NON TABS
	RESCRI	OF SUE	Acid (ASPIRI 50 mg bs 500 mg rup 120mg Sr	an 50m Inj 2% enfamme 1455 Ang fire firej fingtin ilin Cace 250mg ovaattist tabe 400mg 80mg ovaattist tabe 400mg 80mg andro tabe 800mg discoe tabe 800mg	encilin taba 2 s 500mg s 500mg s 125mg/5m den 125mg/5m den 126mg/5m den 126mg/5m	Nor Fini 5 MU Wrini 250 mg Por Fini 1 g	r Fontried Pdr J Caps 250mg 50mg * F Ini to	compan lej actile tates 200mg datade tates 100mg ottode tates 100mg	pound (WHTE) ethine 20120 (Intere 20120 (ntrine 201120 : rogimi methanine 50 Ding	100 mg	pm 001 s	rg ole Add table	e BPC Compounds s (DRS) for 1 IB	Omimuet Sym	H	To # Bhinylestradio 0.03 mg 75 mg MiCROGYNON TABS
TE:	E	TYPE	Acetylasicyclic Acid (ASPRIN) (stra 30) Dictornac taba 50 mg Permoetamol taba 500 mg Permoetamol taba 500 mg	Lignoram Sum Inj 2% Chlorphenearmen table Ang Auteratine Titri Ing Img Im Americitin Capes (56mg Controlling Capes table 400mg 80mg 050copcine table 100mg 050copcine table 700mg 050copcine table 700mg	Prenovynetny Pencin Iala 250mg Opratovach Iala 500mg Erythrenych Garules 125mg/5ml Antorcilin Grarules 125mg/5ml/100ms Continnource 5.6 strendom Zatrick Bencaline Bencaline Pencilin Fostield Paris Inc.	Bertyl Fencilin Par F Inj 5 MU Cethaxona Powder Inj 250 mg Chioramphenicol Por F Inj 1 g	Proceine Persoliin Fontled Pd Chlorangrenool Caps 250mg Clovendiin Caps 250mg 16 Cethresone Par F Ini 1g	Spectroomycin ley Alberdatole table 200mg Metendatole table 100mg Orthomote Deservice	poic Acid Com methen/Lumita methen/Lumita methen/Lumita	Artimetran Lunistantina 20120 ng Narau Outrne 2mi ing 200-gow Sulphutowie + Pyrimetraniae 200mg/25mg Outrie Sulphus 200mg	Artenunate Inj 60mg Aminophylline table 100 Epitedrine table 30 mg	Otherpromatine tails 100 mg	Premiji con tatos 100mg Ferroun Suchata + Foli	Zire Sidpate Magnesum Tristicate BPC Compound tabe Oral Phylotation salls (ORS) for 1 line powde	Orytemacycline Eye commune Tage hystorne N-Butybronnick tage agementer Inthig date grup CO	greaum Suphete M	gestrel 0.15mg us Pumearate 75
e rad	artes	T	126.20		E O D & O B	805	2995	Spectu Alberd Mittem Cloning	Benzo Arterna Arterna	Arte Suite Outr	And	Chine of	Famo	Zhe 3 Magn Oal R	Okyter Hycelo	Magne	Leveno + Farro
ERT	TEKELE GUMA NOTELI	4 90	9	20	10		DAL 14	THE							-		
MARY	NOFLI	li	5	20		-			24		The set	1-10-			1 Million		
NAB	SAMOND	72	9 8 (1 9 9 1 8 9 1 8 9 5	20			tti							1			
ALIA	ABANLA	52	18	3)					24		and-						
AW	ABONLLA	2/1	5				111	111	24-6		1	110					
10	ISSA Richiwai	22	18						0								
RIFA	KICLOWA	3	1		10 10			111							-		
RG	JAIA1 JONAS	22	18				1		1 10 11		1						
NY	NEENT	4	9	10					1				1				
150	NILLI	4 1%	5	, 20 5, 1		1											



Conclusions and Recommendations

- Poor data quality, underreporting in DHIS2 and lack of data ownership
- Dispensing of Multiple blisters due to shortage/short expiry of Paediatric formulations
- Calculated Vs Actual Consumption? Need to review tools
- •
- Need for linking eLMIS consumption data and DHIS2 with auto check features



Acknowledgement

- USAID Tanzania
- USAID Boresha Afya Southern zone
- Morogoro Region RHMT
- Morogoro Municipality CHMT
- LMU





Thanks to our generous sponsors





World Health Organization







